2A!"99$K;T>l!&:G?7F08~$r%l%]!<%H!#(J
$B!|(JWhat' New
$BD4::%l%]!<%H(J[$B93BN0eLt!&J,;RI8E*Lt(J]$B!]$=$N!](J2011$B$rH/9T$7$^$7$?!#(J
$B?74)!*!!>\:Y"*(Jhttp://www.medmk.com/ykk/ ;2011.1.11
|
$BK\%a%k%^%,$O!"DL4,(J1234$B9f(J[2006.5.8]$B$h$j!"D>Aw$+$i!"!V$^$0$^$0!W7PM3$NG[?.$K@Z$jBX$($F$*$j$^$9!#(J
$B$^$@!V$^$0$^$0!WG[?.$K@Z$jBX$($F$$$J$$$+$?$O!"@'Hs$*?=$79~$_$/$@$5$k$h$&$*4j$$CW$7$^$9!#(J
$B!Z%a%k%^%,9XFI!&Cf;_![!!(Jhttp://www.medmk.com/mm/mailmg/mailmg_ty.htm
$B!Z%a%k%^%,G[?.![!!!!!!!!(J$B$^$0$^$0!!(J[$B%^%,%8%s(JID: 0000200844]
| $BBh(J1353-4$B9f$N%H%T%C%/!*(J[2010.] |
|
2$B7?E|G"IB<#NELt%V%m%b%/%j%W%A%s(J(Cycloset - VeroScience)
$BB?H/@-9E2=>I$N7P8}<#NELt%U%#%s%4%j%b%I(JFingolimod (Gilenya - Novartis)
$B=w@-$N@-5!G=>c32<#NELt(J
$B$6al<#NELt%/%j%s%@%^%$%7%s(J-$B%H%l%A%N%$%sG[9g%2%k(J(Veltin Gel - Stiefel)
$B!ZC;?.$B$r>5G'$7$?!#!!%V%m%b%/%j%W%A%s%a%7%k;@1v(J(Parlodel$BB>!(%Q!<%m%G%k>{(J2.5mg$BB>!K$OG~3QM3Mh$N%I%Q%_%s%"%4%K%9%H$G!"(J20$BG/0J>eA0$+$i9b%W%m%i%/%A%s7l>I!"@hC<5pBg>I!"%Q!<%-%s%=%sIB!"2<;h@E;_ITG=>I8u72$N<#NE$KMQ$$$i$l$F$$$k!#(J
$B!ZF|K\8lHG%3%a%s%H(J1353-4$B!A(J2$B7?E|G"IB<#NELt%V%m%b%/%j%W%A%s(J(Cycloset - VeroScience)$B![(J
$B!!7P8}E|G"IBLt;T>l$O!"8=:_$^$G%0%j%?%>%s7O(J($B%T%*%0%j%?%>%s(J($B%"%/%H%9(J[$BIpEDLtIJ(J])$BEy(J)(2010$BG/Gd>e9b$O(Jrosiglitazone[Avandia]$B$,A0G/Hf(J-43%$B$NBgI}8:$G(J574$B2/1_(J($B!r(J440m)$B!"%"%/%H%9$OA0G/JB$_$N(J3,850$B2/1_(J)$B$,l$7?7$?$J6ILL$r7^$($F$$$k!#!!@h$:(JDPP-4$BAK32Lt!#?)8e$K>C2=4I$+$iJ,Hg$5$l$k%$%s%/%l%A%s$N7lE|9_2<:nMQ$KCeL\$7$?Lt:^$G!"%$%s%/%l%A%s$O?)8e$K>C2=4I$+$iJ,Hg$5$l!"7lE|0MB8E*$K%$%s%9%j%sJ,HgB%?J$*$h$S%0%k%+%4%sJ,HgM^@)$KF/$-7lE|$rD4@a$9$k!#%$%s%/%l%A%s$NJ,2r9ZAG$G$"$k(JDPP-4$B$rAK32$9$k7P8}7lE|9_2{!W(J(MSD$B{!W(J($B>.LnLtIJ9)6H(J)($B0lHLL>!'%7%?%0%j%W%A%s(J)2009.12.11$BH/Gd(J(EU$B>5G'(J2007.4.5$BJF>5G'(J2006.10)$B!"FsHV{(J50mg$B!W(J($B0lHLL>!'%S%k%@%0%j%W%A%s(J/vildagliptin$B!K(JLAF237/Galvus(R)[$B%N%P%k%F%#%9(J $B%U%!!<%^(J]$BH/Gd(J2010.4.16(EU$B>5G'(J2007.9.28)$B!";0HV{(J6.25mg$B!"F1(J12.5mg$B!"F1(J25mg$B!W(J($B0lHLL>(J $B%"%m%0%j%W%A%s0BB)9a;@1v(J Alogliptin)/SYR-322[$BIpEDLtIJ9)6H(J]$BH/Gd(J2010.6.15$B$HF|K\$G$O#3$K;MHV5G':Q$_!#!!3+H/ES>e$G$O!"(JBI1356(ONDERO(R);Linagliptin)[$BF|K\%Y!<%j%s%,!<%$%s%2%k%O%$%`(J]P3$B!"(JMP-513$B!J%F%M%j%0%j%W%A%s(JTeneligliptin$B!K7P8}:^(J[$BEDJU;0I)(J]P3$B!"(JTA-6666[$BEDJU;0I)(J]P1/2$B!"(JSK-0403[$B6=OB(J/$B;0OB2=3X8&(J]P3$B!"(JKRP-104$B>{(J[$B0INS@=Lt(J]P2$B!"(JDSP-7238$B7P8}:^(J[$BBgF|K\=;M'@=Lt(J]P1/2($B2$=#(J)$B!"(JSYR-472$B7P8}:^(J[$BIpEDLtIJ9)6H(J]P1/2$B!"(JTAK-100$B7P8}:^(J[$BIpEDLtIJ9)6H(J]P1/2$B!#!!%8%c%L%S%"$N(J2010$BG/@$3&Gd>e$O4{$K%H%C%W@=IJ%"%/%H%9$N#73dD6$N(J2764$B2/1_(J($3,339$BI4K|(J,2010$BG/(JJanumet$B9g;;(J)$B$HBh(J2$B0L!#!!%(%/%">{(J($B2$JF(JGalvus)$B$O(J324$B2/1_(J($391m)$B!"(JOnglyza$B$O(J188$B2/1_(J(AstraZeneca $69m+BMS$B
GLP-1$Be$2$k%[%k%b%s$G$"$k%0%k%+%4%s$NJ,Hg$rM^@)$9$k#27?E|G"IB<#NELt!#!!%j%i%0%k%A%I(J($B0dEA;RAH49$((J)($B%S%/%H!<%6Hi25G'(J2009.6.30)$B$O9qFb=i!#!!@$3&$G$O(J2009$BG/8eH>$K=iEP>l$7!"(J2010$BG/Gd>e9b(J2,317$BI4K|(JDKK($BLs(J346$B2/1_(J)$B$H=gD4$GJF9q(JGLP-1$B;T>l$N(J27%$B$KC#$7$F$$$k!#!!@$3&=i$N(JGLP-1$B5G'(J2006.11.20)$B$G!"(J2010$BG/@$3&Gd>e9b(J$710.2$BI4K|(J($BLs(J588$B2/1_(J)$B!#!!0lDj$N0LCV$r3NJ]$7$?!#!!3+H/Cf$N$b$N$H$7$F$O(JAVE0010($B%j%-%7%;%J%A%I(J/lixisenatide)[$B%5%N%U%#!&%"%Y%s%F%#%9(J]P3$B!"(JR1583$B!!Cm(J(ITM-077)(Taspoglutide)[$BCf30@=Lt(J/$BDk?M%U%!!<%^(J]]P2$B!#(J
SGLT2$BAK32:^$O!"?UB!G":Y4I$G$NE|$N:F5[<}$rM^@)$7!"E|$rG"Cf$KGS=P$5$;$k$3$H$G7lE|CM$r2<$2$k?7$7$$%a%+%K%:%`$N#27?E|G"IB<#NELt$G!"(JASP1941$B!!7P8}(J[$B%"%9%F%i%9@=Lt(J]P3$B!"%@%Q%0%j%U%m%8%s(J/dapagliflozin(BMS-512148)[$B%"%9%H%i%<%M%+(J/$B%V%j%9%H%k!&%^%$%d!<%:(J]P3($BJF2$?=@A(J)$B!"(JKGA-3235(DSP 3235)$B7P8}:^(J[$B%-%C%;%$LtIJ(J;$BBgF|K\=;M'(J]P1/2$B!"(JTA-7284($B%+%J%0%j%U%m%8%s(J)[$BEDJU;0I)(J]P2$B!"(JCSG452$B7P8}(J(R7201)[$BCf30@=Lt(J]P2$B!"(JBI 10773[$BF|K\%Y!<%j%s%,!<%$%s%2%k%O%$%`(J]P2/3$BEy!#9q:]E*$KL$>5G'!#(J
$B!!"*>\:Y$O;29M;qNA!|(JML$B%j%=!<%9!'E|G"IB<#NELt(J[antidiabetes.htm]$B!|(JML$B%j%=!<%9!'E|G"IB(J[mp_diabetes.htm]$B$KE;$a$?!#(J
$B!ZMWLs![(J
$B!&@.?M(J2$B7?E|G"IB$N<#NELt$H$7$F!"0JA0$+$i9b%W%m%i%/%A%s7l>I!"@hC<5pBg>I$J$I$N<#NE$KMQ$$$i$l$F$$$?G~3QM3Mh%I%Q%_%s%"%4%K%9%H!&%V%m%b%/%j%W%A%s%a%7%k;@1v$N?7$7$$>{:^$,>5G'$5$l$?!#(J
$B!&E|G"IB$N<#NE$K$*$1$k%V%m%b%/%j%W%A%s$N:nMQ5!=x$OITL@$@$,!";k>22
$B!&NW>2;n83$G<($5$l$?7lE|Dc2<8z2L$O$o$:$+$G!"$H$-$KG&MF:$Fq$J0-?4$dSREG$r0z$-5/$3$9!#(J
$B!!F|K\8lHGCp!K(Jbromocriptine mesylate (Cycloset Tabs [VeroScience LLC])
$B!!!ZJLL>![!!!Z3+H/85![(JVeroScience, LLC$B!!(J [DBR_ID]x
$B!!!Z2=3XL>![(J[Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'$B&A(J)-]. CYCLOSET is a single enantiomer with absolute configuration 5R, 8R, 2$B!G(JR, 5$B!G(JS, 11$B!G(JS, 12$B!G(JS.
$B!!!Z>5G'![(JFDA$B?=@A(J=$B!"(JFDA$B>5G'(J=May 05, 2009 (VeroScience, LLC)$B!"H/GdF|(J=2010.11.15($BHNGd(JSantarus, Inc);$B!!!Z@=:^![(JTablets: 0.8 mg bromocriptine mesylate$B!!!ZE,1~![(JCYCLOSET is a dopamine receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.$B!!!ZMQK!MQNL![=i2s#1F|#12s#1>{(J(0.8mg)$B!"=5C10L$GA}NL2D!"(J1.6-4.8mg$BKx(J
$B!!!Z:nMQ![(JCYCLOSET contains bromocriptine mesylate, an ergot derivative that is a dopamine receptor agonist. The mechanism by which CYCLOSET improves glycemic control is unknown. Morning administration of CYCLOSET improves glycemic control in patients with type 2 diabetes without increasing plasma insulin concentrations. Once daily morning administration of CYCLOSET to humans increases circulating levels of bromocriptine, a dopamine receptor agonist, for 4-5 hours after administration.$B!!!ZFCD'![;ie$5$;$kG=NO$rDL$7$F!"%?%$%W(J II$BE|G"IB$N<#NE$KLrN)$D(J
$B!Z@=IJ>pJs![(Jwww.cycloset.com$B!!!ZE:IUJ8=q![(JCYCLOSET Prescribing Information
$B!!!ZDs7H![(J[$B5-;v(J]$BJF9q(JS2 Therapeutics, Inc$B$BJF(JSantarus, Inc.$B$,(J2010.9.8.Cycloset$B$NJF9qHNGd8"$r3MF@(J$B!!!Z(JEU$B![!!(J
$B!ZF|K\![L$3+H/!!!Z$=$NB>![(J
$B!!F|K\8lHGCp!K%V%m%b%/%j%W%A%s%a%7%k;@1v(Jbromocriptine mesylate (Parlodel[Novartis])$B%Q!<%m%G%k(J
$B!!!ZJLL>![(JCB154;2-bromo-$B&A(J-ergocryptine mesylate$B!J(JJAN$B!K!((JParlodel($B%9%$%9!"%"%a%j%+!"%$%.%j%9(J $BB>?t==%u9q!K(JPravidel($B%I%$%D!"%9%&%'!<%G%s(J)$B!!!Z3+H/85![(JNovartis$B!!(J [DBR_ID]14687-2490
$B!!!Z2=3XL>![(JErgotaman-3$B!-(J,6$B!-(J,18-trione, 2-bromo-12$B!-(J-hydroxy-2$B!-(J-(1-methylethyl)-5$B!-(J-(2-methylpropyl)-, (5$B!-&A(J)-mono-methanesulfonate (salt). CAS-22260-51-1$B!J(JBromocriptine Mesilate$B!K(JCAS-25614-03-3$B!J(JBromocriptine$B!K(J
$B!!!Z>5G'![(JFDA$B?=@A(J=$B!"(JFDA$B>5G'(J=28-Jun-1978 ;$B!!!Z@=:^![(JEach Parlodel® (bromocriptine mesylate) SnapTabs® tablet for oral administration contains 2.5 mg and each capsule contains 5 mg bromocriptine (as the mesylate).
$B!!!ZE,1~(J1 -Hyperprolactinemia-Associated Dysfunctions$B![(JParlodel® (bromocriptine mesylate) is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Parlodel treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations.
Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of Parlodel therapy may be used to reduce the tumor mass prior to surgery.
$B!!!ZE,1~(J2 -Acromegaly$B![(JParlodel therapy is indicated in the treatment of acromegaly. Parlodel therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately 1/2 of patients treated, although not usually to normal levels.
Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with Parlodel offers potential benefit before the effects of irradiation are manifested.
$B!!!ZE,1~(J3 -Parkinson$B!G(Js Disease$B![(JParlodel SnapTabs® or capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson$B!G(Js disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), Parlodel therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing $B!H(Jend of dose failure$B!G!G(J on levodopa therapy. Parlodel therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function ($B!H(Jon-off$B!G!G(J phenomenon). Continued efficacy of Parlodel therapy during treatment of more than 2 years has not been established.
Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson$B!G(Js disease with Parlodel. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in Parlodel treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for Parlodel therapy.
$B!!!ZMQK!MQNL![(J[Hyperprolactinemic Indications]$B=i2s#1F|#12s(J0.5mg-2.5mg$B!"NW>28&5f$K$h$k;jE,MQNL$O@.?M$G#1F|(J2.5-15mg$B!">.;y$O#1F|(J2.5-10mg$B!!(J[Acromegaly]$B=i2s#1F|#12s(J0.5mg-2.5mg$B!";jE,MQNL$O@.?M$G#1F|(J20-30mg$B!":GBg(J100mg$B!!(J[Parkinson$B!G(Js Disease]$B=i2s(J0.5mg-2.5mg$B$r#1F|(J2$B2s!"#2=5Kh$KA}NL2D!":GBg(J100mg
$B!!!Z:nMQ![!!!ZFCD'![!{NW>2E*$KM-MQ$J:G=i$N;}B3@-%I%Q%_%s:nF0Lt$G$"$k!#!!!{2o$K$h$kGSMq>c32$K$*$$$FGSMq@-<~4|$HG%UT@-$r2sI|$5$;$k!#!!!{F}=AO3=P$r7Z8:$7!";:js@-F}=AJ,Hg$rM^@)$9$k!#!!!{KvCI$N7lCf@.D9%[%k%b%sCM$rDc2<$5$;!"3FI>u$r2~A1$9$k!#!!!{@~>rBN$N%I%Q%_%s
$B!!!ZE:IUJ8=q![(JParlodel -PI
$B!!!ZDs7H![!!!Z(JEU$B![9q:]CB@8G/7nF|(J1975 $BG/(J11 $B7n!!(J
$B!ZF|K\![(J$B%Q!<%m%G%k(J2.5mg[$B%N%P%k%F%#%9(J]$B>5G'(J1978.8.1$B!"Lt2A<}:\(J1979.4.19$B!"H/Gd(J1979.4.19$B!!!Z@=:^!AF|K\![#1>{Cf%a%7%k;@%V%m%b%/%j%W%A%s!JF|6I!K(J2.87 $B-S!J%V%m%b%/%j%W%A%s$H$7$F(J2.5 $B-S!K$r4^M-$9$k!#!!!ZE,1~!AF|K\![!;;:js@-F}=AJ,HgM^@)!"F}=AO3=P>I!!!{9b%W%m%i%/%A%s7l@-GSMq>c32!!!{9b%W%m%i%/%A%s7l@-2l9g$K8B$k!K!!!{KvCI!"2I!!!{%Q!<%-%s%=%s>I8u72!!!ZMQK!MQNL!AF|K\![!{;:js@-F}=AJ,HgM^@)!"F}=AO3=P>I!{9b%W%m%i%/%A%s7l@-GSMq>c32!{9b%W%m%i%/%A%s7l@-2l9g$K8B$k!K!ADL>o!"%V%m%b%/%j%W%A%s$H$7$F#1F|#12s(J2.5$B-S$rM8e$K7P8}EjM?$7!"8z2L$r$_$J$,$i#1F|(J5.0$B!A(J7.5$B-S$^$GA2A}$7!"#2!A#32s$KJ,$1$F?)D>8e$K7P8}EjM?$9$k!#$J$*!"G/Np!&>I>u$K$h$jE,59A}8:$9$k!#(J
$B!{KvCI!"2I!ADL>o!"%V%m%b%/%j%W%A%s$H$7$F#1F|(J2.5$B!A(J7.5$B-S$r#2!A#32s$KJ,$1$F?)D>8e$K7P8}EjM?$9$k!#$J$*!"G/Np!&>I>u$K$h$jE,59A}8:$9$k!#(J
$B!{%Q!<%-%s%=%s>I8u72!ADL>o!"%V%m%b%/%j%W%A%s$H$7$F#1F|#12s(J1.25$BKt$O(J2.5$B-S$rD+?)D>8e$K7P8}EjM?$+$i;O$a!"#1Kt$O#2=5Kh$K#1F|NL$H$7$F(J2.5$B-S$:$DA}NL$7!"0];}NL!JI8=`#1F|(J15.0$B!A(J22.5$B!K$rDj$a$k!##1F|NL$O%V%m%b%/%j%W%A%s$H$7$F(J5.0$B-S$N>l9g$OD+?)5Z$SM8e$K!"(J7.5$B-S0J>e$N>l9g$OKh?)D>8e$KJ,$1$F7P8}EjM?$9$k!#$J$*!"G/Np!&>I>u$K$h$jE,59A}8:$9$k!#!!!ZE:IUJ8=q!AF|K\@=Lt(J/$B%N%P%k%F%#%9(J]$B?=@A(J2010.12.10$B!K$NHNGd$r>5G'$7$?!#!!%U%#%s%4%j%b%I$OK\E,1~>I$KBP$7$F=i$a$F>5G'$5$l$?7P8}<#NELt!#(J
$B!ZF|K\8lHG%3%a%s%H(J1353-4$B!A![B?H/@-9E2=>I$N7P8}<#NELt%U%#%s%4%j%b%I(JFingolimod (Gilenya - Novartis)
MS$B$O!"=EFF$G$"$j3n$D>c32$r0z$-5/$3$9!"I@-<@455Z$S<+8JLH1V<@45$G$"$j!"H/IB$N%T!<%/$O(J20$BBe$G$"$k!#$[$H$s$I$N8DBN$O!"3:<@45$N:FH/422r7?$r<($7!"$=$7$F:FH/@-$NH/:n$r7P83$7!"7k2L$H$7$F!"D94|$K$o$?$j!"1JB3E*$J?HBNE*>c325Z$SG'<1?jB`$rC_@Q$9$k!#$3$l$i8DBN$NLs(J70$B!s$,!"EY=E$J$k:FH/$rH<$C$F$^$?$OH<$o$:$K!"?J9T@-$N?@7P3XE*?jB`!JFs/$J$$!#BgItJ,$N45L?$rM-$9$k!#(J
$B&B(J-$B%$%s%?!<%U%'%m%s$O!"=EFF$JM-32;v>]$r@8$:$k2DG=@-$,$"$j!"99$K&B(J-$B%$%s%?!<%U%'%m%s$KBP$7$F@8$8$kCfOB93BN$O!"B>$N%$%s%?!<%U%'%m%s$H8r:9H?1~$7M-8z@-$r<:$o$;!"7k2L$H$7$F!"9g=09q$N$_$G$b!"2a5n$K<#NE$5$l$F$$$?(J5$BK|?M0J>e$N45'$($kO@5D$b$"$k!#!!B?H/@-9E2=>I$N<#NE%,%$%I%i%$%s(J2010$B$O#8G/$V$j$K2~D{!#(J
$B!!F|K\$NB?H/@-9E2=>I45Z8rIU7o?t$H$7$FJ?@.(J21$BG/EY(J14,227$B?M!#(J
$B!!(J2010$BG/EY@$3&;T>l$OGd>e9b%Y!<%9$G!"(JIFN$B@=:^$G$O!"(JAvonex[Biogen-IDEC;IFN$B&B(J1a]$2518.3m(2,085$B2/1_(J),Rebif[Merck-Serono;IFN$B&B(J1a]Eur1668m(1844$B2/1_(J),Betaferon/Betaseron[Bayer AG;IFN$B&B(J1b]EURm1206(1,333$B2/1_(J),Extavia [Novartis;IFN$B&B(J1b]$124m(103$B2/1_(J)$B!!7W(J4365$B2/1_!#!!7P8}(Jglatiramer$B@=:^(JCopaxone[Teva]$3316m(2,745$B2/1_(J),Copaxone[Sanofi-Aventis]$B?dDj(JEUR513m(567$B2/1_(J)$B!!7W(J3312$B2/1_!#!!?7Lt(Jnatalizumab$B@=:^(JTysabri[Biogen-IDEC]$900.2m(745$B2/1_(J)Tysabri[Elan]$851.5m(705$B2/1_(J)$B!!7W(J1450$B2/1_!#!!7P8}(Jdalfampridine$B@=:^(JAmpyra[Acorda;2010.3.1$BH/Gd(J]$133.1m(110$B2/1_(J)$B!!7P8}(Jfingolimod$B:^(JGilenya[Novartis]$15m(12$B2/1_(J)$B!!Am7W(J9249$B2/1_!#(J
$B!!"*>\:Y$O;29M;qNA!|(JML$B%j%=!<%9!'B?H/@-9E2=>I(J$B$KE;$a$?!#(J
$B!ZMWLs![(J
$B!&:FH/7?B?H/@-9E2=>I!J(JMS$B!K$NNW>2E*:FG3$NIQEY$r8:$i$7!"?HBN5!G=>c32$N=8@Q$rCY$i$;$kLt:^$H$7$F!"(JMS$B$N<#NE$G$O=i$N7P8}Lt%U%#%s%4%j%b%I$,>5G'$5$l$?!#(J
$B!&%U%#%s%4%j%b%I$O%j%s;@2=$5$l$F%U%#%s%4%j%b%I%j%s;@1v$H$J$j!"%9%U%#%s%4%7%s(J1-$B%j%s;@
$B!&K\:^$O%$%s%?!<%U%'%m%s&B(J-1a$B$KHf$Y$F:FH/422r7?(JMS$B45/$7!">c32$N?JE8$rCY$i$;$?$,!"=yL.!"(JAV$B%V%m%C%/!"=EFF$J%&%$%k%946@w>I$J$I$NI{:nMQ$,$"$k!#(J
$B!!F|K\8lHGCp!K%U%#%s%4%j%b%I1v;@1v(JFingolimod diHCl(Gilenya - Novartis)($B%,%l%K%"(J)
$B!!!ZJLL>![(JFTY720$B!!!Z3+H/85![(J$BEDJU;0I)@=Lt(J$B!!(J [DBR_ID]
$B!!!Z2=3XL>![(J2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride
$B!!!Z>5G'![(JFDA$B?=@A(J=18-Dec-2009$B!"(JFDA$B>5G'(J=2010.9.22 ;$B!!!Z@=:^![%+%W%;%kCf(JFingolimod diHCl 0.5mg$B!!!ZE,1~![(J($B:FH/422r7?B?H/@-9E2=>I(J) GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.$B!!!ZMQK!MQNL![#1F|#12s(J0.5mg
$B!!!Z:nMQ![(JFingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.$B!!!ZFCD'![!!(J
$B!Z@=IJ>pJs![(Jwww.gilenya.com$B!!!ZE:IUJ8=q![(JGilenya-PI
$B!!!ZDs7H![!!K\:^$O!"5~ETBg3X$NF#B?E/O/65M@655G'$rI<#NELt$H$7$F@=B$HNGd>5G'?=@A$r9T$$$^$7$?!#(J
$B%N%P%k%F%#%9I<#NELt$H$7$F3+H/$r?J$a$F$-$?%9%U%#%s%4%7%s(J1-$B%j%s;@!'%U%#%s%4%j%b%I1v;@1v!K$K4X$7!"%$%s%?!<%U%'%m%s&B$N<#NE$K$b$+$+$o$i$:3hF0@-$N9b$$:FH/422r7?B?H/@-9E2=>I!"$b$7$/$O!"5^B.$K?J9T$9$k=E>I$N:FH/422r7?B?H/@-9E2=>I$K$D$$$F!"2$=#O"9g(J(EU)$B$K$*$$$F=i$N7P8}Lt$H$7$F!">5G'EU$B>5G'(J2011.3.21$B!!(J
$B!ZF|K\![(JFTY720[$BEDJU;0I)@=Lt(J]$B?=@A(J2010.12.10$B!!!!!Z$=$NB>![(J
| $B=w@-$N@-5!G=>c32<#NELt(J |
Drugs for Female Sexual Dysfunction
$B!!@-E*M_5a!"@-E*6=J3!"%*%k%,%:%`!"@-8raVDK$J$I$N@-5!G=>c32$rAJ$($k=w@-$OB?$$(J1$B!#!!$3$NLdBj$K4X$9$kA02s$NK\;o5-;v(J2$B0JMh!"?7$?$K$$$/$D$+$N>pJs$,F@$i$l$?!#(J
$B7kO@!!!]!!JD7P8e=w@-$K$*$1$kg40`=L$K$h$k@-8r:$Fq$K$O!"%(%9%H%m%2%s!"FC$Kg4@=:^$,M-8z$J2DG=@-$,$"$k!#!!0lIt$N=w@-$K$*$1$k@-M_>c32$K$O%"%s%I%m%2%s$N7PHi5[<}:^$,M-8z$J>l9g$,$"$k$,!"=w@-$,;HMQ$G$-$k==J,$KDcMQNL$N@=:^$O8=:_HNGd$5$l$F$*$i$:!"D94|0BA4@-$bL@$i$+$G$J$$!#!!%V%W%m%T%*%s$,M-8z$J2DG=@-$O$"$k$,!"%G!<%?$O8B$i$l$k!#!!(JZestra$B$O0lIt$N=w@-$K$*$$$F@->WF0$rA}2C$5$;$k$3$H$,Js9p$5$l$F$$$k(JOTC$B$N6I=jMQ:^$@$,!"@-4o<^G.46$r0z$-5/$3$92DG=@-$,$"$k!#(J
$B!ZF|K\8lHG%3%a%s%H(J1353-4$B!A=w@-$N@-5!G=>c32<#NELt![(J
$B!!"*>\:Y$O;29M;qNA!|(JML$B%j%=!<%9!'KV5/ITA4<#NELt(J$B$KE;$a$?!#(J
$B!ZMWLs![(J
$B!&=w@-@-5!G=>c32$K4X$9$kA02s$NK\;o5-;v0JMh!"?7$?$J>pJs$,F@$i$l$?$N$G$^$H$a$?!#(J
$B!&g40`=L$K$h$k@-8r:$Fq$K$O!"%(%9%H%m%2%s$NFC$Kg4@=:^$,M-8z!#(J
$B!&@-M_>c32$K$O%"%s%I%m%2%s$N7PHi5[<}:^$,M-8z$J>l9g$,$"$k$,!"D94|0BA4@-$OITL@!#(J
$B!&(JOTC$B$N(JZestra$B$O@->WF0$rA}2C$5$;$k$3$H$,$"$k$HJs9p$5$l$F$$$k$,!"@-4o<^G.46$r0z$-5/$3$92DG=@-$,$"$k!#(J
| $B$6al<#NELt%/%j%s%@%^%$%7%s(J-$B%H%l%A%N%$%sG[9g%2%k(J(Veltin Gel - Stiefel) |
Clindamycin-Tretinoin (Veltin Gel) for Acne
$B!!936]Lt$N%/%j%s%@%^%$%7%s%j%s;@%(%9%F%k(J1.2%$B$H%l%A%N%$%I$N%H%l%A%N%$%s(J0.025%$BG[9g:^(JVeltin Gel$B!J(JStiefel$B!(F|K\L$3+H/!K$,!"(J12$B:P0J>e$N?R>o@-$6al$N6I=jMQ<#NELt$H$7$F(JFDA$B$K>5G'$5$l$?!#!!F1$83h@-@.J,$r4^$`G[9g:^(J(Ziana$B!(F|K\L$3+H/(J)$B$,!"4{$K(J2006$BG/$+$i;THN$5$l$F$$$k!#(J
$B7kO@!!!]!!?7$7$$%/%j%s%@%^%$%7%s%j%s;@%(%9%F%k$H%H%l%A%N%$%s$NG[9g:^!J(JVeltin Gel$B!K$O!"$=$l$>$l$rC1:^$G;HMQ$9$k$h$j$bM-8z$G$"$k!#!!K\:^$,!"4{$K;THN$5$l$F$$$k%/%j%s%@%^%$%7%s%j%s;@%(%9%F%k!?%H%l%A%N%$%s%2%k!J(JZiana$B!K$d!"B>$N%l%A%N%$%I$H936]Lt$NJ;MQ$KHf$Y$F$I$&$+$OL$$@L@$i$+$G$J$$!#!!G[9g:^$OJXMx$@$,!"3F@.J,$N%8%'%M%j%C%/@=:^$rF1;~$KEjM?$7$?$[$&$,0B2A$G$"$k!#(J
$B!ZF|K\8lHG%3%a%s(J1353-4$B%H!A$6al<#NELt%/%j%s%@%^%$%7%s(J-$B%H%l%A%N%$%sG[9g%2%k(J(Veltin Gel - Stiefel)$B![(J
$B!!"*>\:Y$O;29M;qNA!|(JML$B%j%=!<%9(J:$B:Cal(J,$B4%a}<#NELt(J$B$KE;$a$?!#(J
$B!ZMWLs![(J
$B!&(J12$B:P0J>e$N?R>o@-$6al$N<#NELt$H$7$F!"936]Lt$N%/%j%s%@%^%$%7%s%j%s;@%(%9%F%k(J1.2%$B$H%l%A%N%$%I$N%H%l%A%N%$%s(J0.025%$B$NG[9g:^(JVeltin Gel$B$,>5G'$5$l$?!#(J
$B!&K\G[9g:^$O@.J,Lt:^$NC1:^EjM?$h$j$bM-8z$@$,!"@h9T$NF1$8@.J,$NG[9g:^(JZiana$B$dB>$N%l%A%N%$%I!\936]LtJ;MQNEK!$H$NHf3S$O9T$o$l$F$$$J$$!#(J
$B!&$6al$N<#NELt$K$O%8%'%M%j%C%/$N936]Lt!"%l%A%N%$%I$,J#?t$"$j!"$=$l$i$rJ;MQ$7$?$[$&$,0B2A(J
$B!!F|K\8lHGCp!K%/%j%s%@%^%$%7%s(J-$B%H%l%A%N%$%sG[9g%2%k(J/clindamycin-tretinoin(Veltin Gel - Stiefel)
$B!!!ZJLL>![!!!Z3+H/85![(JStiefel Laboratories, Inc.[$BJF(J](GSK$B;R2q
$B!!!Z2=3XL>![(J
$B!!!Z>5G'![(JFDA$B?=@A(J=$B!"(JFDA$B>5G'(J=16-Jul-2010 ;$B!!!Z@=:^![(JTopical gel: clindamycin phosphate 1.2% and tretinoin 0.025% in 30 gram tubes$B!!!ZE,1~![(JVELTIN Gel is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older$B!!!ZMQK!MQNL![#1F|#12sM
$B!!!Z:nMQ![!Z(JTretinoin$B![(J Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.$B!!!Z(JClindamycin$B![(J binds to the 50S ribosomal subunit of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Clindamycin has been shown to have in vitro activity against Propionibacterium acnes (P. acnes), an organism that has been associated with acne vulgaris; however, the clinical significance of this activity against P. acnes was not examined in clinical studies with VELTIN Gel. P. acnes resistance to clindamycin has been documented.$B!!!ZFCD'![!!(J
$B!Z@=IJ>pJs![(Jwww.veltingel.com$B!!!ZE:IUJ8=q![(JVeltin Gel - PI
$B!!!ZDs7H![!!!Z(JEU$B![!!(J
$B!ZF|K\![L$3+H/!!!Z$=$NB>![(J
| $B!ZC;?.![MU;@G[9g7P8}HrG%Lt(JBeyaz(Bayer) |
An Oral Contraceptive with Folate
$B!!(JFDA$B$N;pLd0Q0w2q$,!"7P8}HrG%Lt$HMU;@$r4^$`G[9g>{$r3+H/$9$k$h$&4+9p$r=P$7$F$+$i(J6$BG/$,$?$A(J1$B!"(JFDA$B$O7P8}HrG%Lt(JYaz 2$B$HMU;@$N5G'$7$?(J3$B!#!!(JFDA$B$K$h$k$H!"(J18$B!A(J40$B:P$N7r>o=w@-(J379$BNc$rBP>]$KJF9q$Ge>:$5$;$?!#!!F1MM$N7P8}HrG%Lt$H(Jlevomefolate$B$NG[9g:^$r;HMQ$7$?L$H/I=$N%I%$%D$N8&5f!JE:IUJ8=q$K5-:\!K$G$O!"MU;@G;EY$O>e>:8e(Jlevomefolate$B$NEjM?Cf;_8e$b9bCM$r0];}$7$?(J4$B!#(J
$B!ZF|K\8lHG%3%a%s%H(J1353-4$B!A!ZC;?.![MU;@G[9g7P8}HrG%Lt(JBeyaz(Bayer)$B![(J
$B!!"*>\:Y$O;29M;qNA!|(JML$B%j%=!<%9(J:$B7P8}HrG%Lt(J$B$KE;$a$?!#(J
$B!!F|K\8lHGCp!K(JBeyaz[Bayer Healthcare Pharmaceuticals]$B!A(Jdrospirenone, ethinyl estradiol (EE) as betadex clathrate and levomefolate calcium
$B!!!ZJLL>![!!!Z3+H/85![(JBayer HealthCare Pharmaceuticals[GE]$B!!(J [DBR_ID]
$B!!!Z2=3XL>![(J
$B!!!Z>5G'![(JFDA$B?=@A(J=Aug 21, 2009$B!"(JFDA$B>5G'(J=2010.9.27 ;$B!!!Z@=:^![(JBeyaz consists of 28 film-coated, biconvex tablets in the following order:$B!!(J1)24 pink tablets, each containing 3 mg drospirenone (DRSP), 0.02 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefolate calcium$B!!(J2)4 light orange tablets, each containing 0.451 mg levomefolate calcium$B!!!ZE,1~![(JBeyaz is an estrogen/progestin COC containing a folate, indicated for use by women to: 1)prevent pregnancy. $B!!(J2)treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception. $B!!(J3)treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. $B!!(J4)raise folate levels in women who choose to use an oral contraceptive for contraception. $B!!!ZMQK!MQNL![#1F|#12s#1>{(J
$B!!!Z:nMQ![!!!ZFCD'![(Jlevomefolate$B%+%k%7%&%`$OMU;@$NBeoMQ$9$k?M!"0{
$B!Z@=IJ>pJs![(Jwww.beyaz.com$B!!!ZE:IUJ8=q![(JBeyaz-PI
$B!!!ZDs7H![!!!Z(JEU$B![!!(J
$B!ZF|K\![L$3+H/!!!Z$=$NB>![(J
$BD4::%l%]!<%H(J[$B93BN0eLt!&J,;RI8E*Lt(J]$B!]$=$N!](J2011$B$rH/9T$7$^$7$?!#(J
$B?74)!*!!>\:Y"*(Jhttp://www.medmk.com/ykk/ ;2011.1.11
|
$B4k2hJT=8!!!!!!!!!!!!!!L@F|$N0eLt$r9M$($k2q(J
$BH/9T!!!!!!!!!!!!!!!!!!3t<02q.?{(J
103-0024 $BEl5~ETCf1{6hF|K\66>.=.D.(J12-10
$B6&F1%S%k!J7!N1!K(J5F $B5W1J!u(JCo$B5$IU(J
TEL : 03-3664-2020 FAX : 03-3666-3188 E-Mail :support@medlet.jp
$B!ZH/9T85![!!(J$B3t<02q
$B!ZJT=8?M![!!>.?{!!GnG7(J
$B!Z$*Ld9g$;![(Jsupport@medmk.com
$B!Z%a%k%^%,0JA0$N9f![!!!!(Jhttp://www.medmk.com/mm/mailmg/
$B!Z%a%k%^%,9XFI!&Cf;_![!!(Jhttp://www.medmk.com/mm/mailmg/mailmg_ty.htm
$B!Z%a%k%^%,G[?.![!!!!!!!!(J$B$^$0$^$0!!(J[$B%^%,%8%s(JID: 0000200844]
$B!ZCm!!0U![!!(JHotmail$B$Gl9g!"0lItIT6q9g$,H/@8$7!"$3$NK\%l%]!<%H$N(J
$B!!!!>l9g$b@5>oI=<($5$l$^$;$s!#!!B>$N%a!<%k%"%+%&%s%H$KE>Aw$7$F$b(Jok$B$G$9!#(J
$B!|!V(JThe Medical Letter$BF|K\8lHG!WK\;oFIKvHx$K$"$k!!(Jxxxx-xxxxxxxx $B$H$$$&?t;z$O!"$"$J$?$N(JWEB
ID-Password$B$G$9!#(J[$B9XFIhttp://www.medmk.com/mm/mailmg/
| The Medical Letter$BF|K\8lHG(J |
$B%"%a%j%+$rCf?4$K@$3&3F9q$GH/9T$5$l$k0eLtIJNW>2I>2A%K%e!<%9%l%?!
$B!!K\;o$O0eLtIJ!"FC$K(J$B$9$Y$F$N?7Lt$H4{B8Lt(J$B$N?7$7$$M-MQ@-!&I{:nMQ>pJs$K4X$9$k8x@5$G87L)$+$D:G?7$N(J$B0eLtIJI>2A>pJs(J$B$rKh9fDs6!$7$^$9!#(J
$B!!%"%a%j%+$G#1#9#5#9G/$KAO4)$5$l!"#4#0G/0J>e$K$o$?$C$F!"#2=54V$K#12s!JG/#2#62s!K!">o$K:G?7$N>pJs$rDs6!$7B3$1$k<#NE!&EjLt%^%K%e%"%k$H$7$F!"JF9q$G8=:_#1#5K|It0J>eH/9T$5$l!"2$JF$N0eNE=>;v$B!V(JThe Medical Letter on Drugs and Therapeutics$B!W(J$B$NF|K\8lHG$G$9!#(J
$B!!!{(JWHO$B?d>)(JDrug bulletins[3$BWHO Guide to good prescribing - Annex2: Essential References
$B!!!{J)!"0K!"@>$N3F9q8lHG$b?tK|C10L$NIt?t$rH/9T(J
($BF|K\8lHG$O(J1985$BG/0JMhHG8"$rF@$FK]LuHG$H$7$FH/9T(J)
|
$B!z3t<02qhttp://www.medmk.com/mm/
$B!z%Q%s%U%l%C%H!!(J[html] http://www.medmk.com/mm/meddm.htm
[pdf] http://www.medmk.com/mm/meddm.pdf
$B8+K\$N%Z!<%8(J http://www.medmk.com/mm/ml_sampl.htm
$B!z%X%C%I%i%$%s!J(J1995-2007$B!K(J
$B9f=g(J http://www.medmk.com/mm/ml_nr.htm
$BLt8z=g(J http://www.medmk.com/mm/ml_tc.htm
$B!zK\J8$X$O#I#D$H%Q%9%o!<%I$,I,MW$G$9!#"*%"%/%;%9J}K!(J
http://www.medmk.com/mm/web_id.pdf
$B!z3F%F!<%^Kh$N0eLt;qNA=8(J
http://www.medmk.com/mm/add/ml_add.htm
$B!|;29M;qNA(J
$B0eLtD4::;qNA(J($BDI2C%a%b(J)$B$NJG(J$B$X(J
$B@=Lt3Fe(J($B@$3&(J)$B$X(J
$B@=Lt3Fe(J($B9qFb(J)$B$X(J
$B!V(JFDA$B>5G'?7Lt0lMw!W(J
ML$B;qNA!'(JFDA$B;pLd0Q0w2q!A5DBj(J
| $B%a%k%^%,%j%s%/!&Aj8_%j%s%/(J |
$B!|L5NA%a%k%^%,!V5H@n0eLt7P:Q%l%]!<%H!W(J
$B0FFb!&?=9~$_(J | $B%P%C%/%J%s%P!<(J |$B%a%k%^%,2=0JA0$N4{4)9f(J